

Citalopram (Celexa®)

Citalopram (Celexa®) belongs to a class of antidepressants called selective serotonin reuptake inhibitors (SSRIs). It is primarily used to treat depression.

intermediate_metabolizer+1, based on your genetic result, your body is likely to have a typical response to citalopram (Celexa®).

This means that based on the DNA variants we tested, citalopram (Celexa®) is likely to work as expected for you. However, other factors – such as having a DNA variant not included in this test, certain health conditions, or taking other medications – may influence your response. **Do not use this result to start, stop, or change any course of treatment.** Medications should always be taken as directed.

Likely typical response

to citalopram (Celexa®)

Learn more about your result

GENE	VARIANT(S) DETECTED	OVERALL FUNCTIONAL EFFECT
CYP2C19	*3 (one copy)	Decreased enzyme function

How does my genetic result affect my ability to process citalopram (Celexa®)?

Citalopram is a medication primarily used to treat depression.

Based on your genetic result, you are predicted to be a CYP2C19 intermediate metabolizer.

This means you may process citalopram slightly slower, which may lead to slightly higher levels of citalopram in the body. However, this is not expected to impact your response to citalopram or increase your chance of side effects.

Do not use this result to start, stop, or change any course of treatment. This medication should always be taken as directed. Making changes on your own can lead to side effects or reduce intended benefits of the medication.



Keep in mind



If you are already taking this medication, **continue your treatment as directed** unless your doctor recommends a change.



Other factors besides your genetics can also affect your body's response to this medication.



This test **does not include all possible DNA variants** that may affect your body's response to this medication.



This result **does not apply** to all antidepressants, including fluoxetine and paroxetine.

About citalopram

Also known as: Celexa® (Celexa® is a registered trademark of Forest Laboratories, Inc.)



Primary uses of this medication

Citalopram is used to treat depression. It belongs to a class of antidepressants called selective serotonin reuptake inhibitors (SSRIs).



How this medication works


Serotonin is a chemical messenger that carries signals between brain cells. SSRI antidepressants help treat depression by increasing levels of serotonin in the brain.

Read more at: [MedlinePlus](#) [Mayo Clinic](#)

Share a summary of your Pharmacogenetics reports with a healthcare professional.

If you ever need treatment with citalopram, a healthcare professional like your doctor or pharmacist may be able to use this report for reference.

Do not use this report to start, stop, or change any course of treatment. Medications should always be taken as directed.



Your Genetic Result

CYP2C19 Drug Metabolism

Predicted intermediate metabolizer



[View report >](#)

References

- Cooke MJ et al. (2013). "Citalopram and cardiac toxicity." *Eur J Clin Pharmacol.* 69(4):755-60. *
- de Vos A et al. (2011). "Association Between CYP2C19*17 and Metabolism of Amitriptyline, Citalopram and Clomipramine in Dutch Hospitalized Patients." *Pharmacogenomics J.* 11(5):359-67. *
- Herrlin K et al. (2003). "Metabolism of citalopram enantiomers in CYP2C19/CYP2D6 phenotyped panels of healthy Swedes." *Br J Clin Pharmacol.* 56(4):415-21. *
- Hicks JK et al. (2015). "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors." *Clin Pharmacol Ther.* 98(2):127-34. *
- Kumar Y et al. (2014). "CYP2C19 variation, not citalopram dose nor serum level, is associated with QTc prolongation." *J Psychopharmacol.* 28(12):1143-8. *
- U.S. Food and Drug Administration. "FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses." Retrieved November 1, 2019, from <https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-revised-recommendations-celexa-citalopram-hydrobromide-related> *
- U.S. Food and Drug Administration (2020). "Table of Pharmacogenetic Associations." Retrieved December 21, 2020 from <https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations> *
- U.S. Food and Drug Administration, Center for Drug Evaluation and Research. "Celexa® (citalopram hydrobromide) NDA 020822 label." Retrieved October 20, 2019 from https://www.accessdata.fda.gov/drugsatfda_docs/label/1998/20822lbl.pdf *
- Yu BN et al. (2003). "Pharmacokinetics of citalopram in relation to genetic polymorphism of CYP2C19." *Drug Metab Dispos.* 31(10):1255-9. *

Change Log

Your report may occasionally be updated based on new information. This Change Log describes updates and revisions to this report.

Date	Change
May 19, 2021	Citalopram (Celexa®) report created.